<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="MicroorganismsMicroorganismsmicroorganismsMicroorganisms2076-2607MDPI pmcid: 7232181 doi: 10.3390/microorganisms8040577microorganisms-08-00577 : Article Staphylococcus aureus Lung" exact="Infection" post="Results in Down-Regulation of Surfactant Protein-A Mainly Caused by"/>
 <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Pneumonia" post="is the leading cause of hospitalization worldwide. Besides viruses,"/>
 <result pre="Pneumonia is the leading cause of hospitalization worldwide. Besides viruses," exact="bacterial" post="co-infections dramatically exacerbate infection. In general, surfactant protein-A (SP-A)"/>
 <result pre="whether influenza A virus (IAV) and/or Staphylococcus aureus (S. aureus)" exact="infections" post="affect SP-A expression. To closely reflect the situation in"/>
 <result pre="lung, we used a human alveolus-on-a-chip model and a murine" exact="pneumonia" post="model. Our results show that S. aureus can reduce"/>
 <result pre="can reduce extracellular levels of SP-A, most likely attributed to" exact="bacterial" post="proteases. Mono-epithelial cell culture experiments reveal that the expression"/>
 <result pre="which is highly produced by professional phagocytes in response to" exact="bacterial infection." post="By using the human alveolus-on-a-chip model, we show that"/>
 <result pre="in vivo. These findings indicate that (I) complex interactions of" exact="epithelial" post="and immune cells induce down-regulation of SP-A expression and"/>
 <result pre="and immune cells induce down-regulation of SP-A expression and (II)" exact="bacterial" post="mono- and super-infections reduce SP-A expression in the lung,"/>
 <result pre="the lung, which might contribute to a severe outcome of" exact="bacterial" post="pneumonia. Staphylococcus aureus pneumonia surfactant protein-A influenza A virus"/>
 <result pre="contribute to a severe outcome of bacterial pneumonia. Staphylococcus aureus" exact="pneumonia" post="surfactant protein-A influenza A virus human alveolus-on-a-chip 1. Introduction"/>
 <result pre="pneumonia surfactant protein-A influenza A virus human alveolus-on-a-chip 1. Introduction" exact="Pneumonia" post="is the most severe inflammatory disease of the lower"/>
 <result pre="human alveolus-on-a-chip 1. Introduction Pneumonia is the most severe inflammatory" exact="disease" post="of the lower respiratory tract and also the most"/>
 <result pre="Introduction Pneumonia is the most severe inflammatory disease of the" exact="lower" post="respiratory tract and also the most common infectious disease"/>
 <result pre="Pneumonia is the most severe inflammatory disease of the lower" exact="respiratory" post="tract and also the most common infectious disease worldwide."/>
 <result pre="of the lower respiratory tract and also the most common" exact="infectious disease" post="worldwide. A wide variety of microorganisms can induce pneumonia,"/>
 <result pre="the lower respiratory tract and also the most common infectious" exact="disease" post="worldwide. A wide variety of microorganisms can induce pneumonia,"/>
 <result pre="Among these, influenza A and B viruses (IAV, IBV) are" exact="primary" post="causative agents [1]. The high mortality rates during the"/>
 <result pre="influenza virus (IV) epidemics and pandemic outbreaks are associated with" exact="bacterial" post="super-infections, and here Staphylococcus aureus (S. aureus), a facultative-pathogenic"/>
 <result pre="a facultative-pathogenic bacterium, is of major importance. S. aureus colonizes" exact="epithelial" post="surfaces, but can also cause a broad spectrum of"/>
 <result pre="epithelial surfaces, but can also cause a broad spectrum of" exact="infections" post="ranging from superficial skin infections to life-threatening diseases, such"/>
 <result pre="cause a broad spectrum of infections ranging from superficial skin" exact="infections" post="to life-threatening diseases, such as bacterial pneumonia [2]. The"/>
 <result pre="ranging from superficial skin infections to life-threatening diseases, such as" exact="bacterial" post="pneumonia [2]. The first line of defense during infections,"/>
 <result pre="from superficial skin infections to life-threatening diseases, such as bacterial" exact="pneumonia" post="[2]. The first line of defense during infections, apart"/>
 <result pre="also surfactant proteins, are principal targets to fight pathogens [5]." exact="Pulmonary" post="surfactant has long been known to be essential to"/>
 <result pre="Pulmonary surfactant has long been known to be essential to" exact="lower" post="the surface tension at the air-liquid interface of the"/>
 <result pre="the air-liquid interface of the lung and to prevent its" exact="collapse" post="at end-expiration. However, surfactant proteins have also immunomodulatory and"/>
 <result pre="immunomodulatory and antimicrobial activity and thereby are important agents in" exact="primary" post="host immune defense [6,7,8]. Surfactant proteins interact with several"/>
 <result pre="aureus [10]. During the IAV invasion into the lung, the" exact="viral" post="hemagglutinin binds to sialic acid residues on the surface"/>
 <result pre="hemagglutinin binds to sialic acid residues on the surface of" exact="epithelial" post="cells to initiate viral internalization [11]. Surfactant protein-A (SP-A)"/>
 <result pre="acid residues on the surface of epithelial cells to initiate" exact="viral" post="internalization [11]. Surfactant protein-A (SP-A) also presents sialic acid"/>
 <result pre="phagocytosis of S. aureus by neutrophils and macrophages and inhibits" exact="bacterial" post="adherence to the epithelial layer, thus preventing the bacterial"/>
 <result pre="by neutrophils and macrophages and inhibits bacterial adherence to the" exact="epithelial" post="layer, thus preventing the bacterial penetration into the host"/>
 <result pre="inhibits bacterial adherence to the epithelial layer, thus preventing the" exact="bacterial" post="penetration into the host cells [13]. Several inflammatory cytokines"/>
 <result pre="macrophages, are known to release large amounts of TNF-α during" exact="bacterial infections" post="[18,19,20,21]. Yet, bacteria can also directly affect pulmonary surfactant"/>
 <result pre="are known to release large amounts of TNF-α during bacterial" exact="infections" post="[18,19,20,21]. Yet, bacteria can also directly affect pulmonary surfactant"/>
 <result pre="during bacterial infections [18,19,20,21]. Yet, bacteria can also directly affect" exact="pulmonary" post="surfactant proteins [22], as S. aureus expresses a cysteine"/>
 <result pre="and other pathogens [23]. Taken together, many parameters during an" exact="infection" post="affect the SP-A expression. In this study, we aimed"/>
 <result pre="aimed to elucidate whether IAV, S. aureus or the combined" exact="infection" post="of both pathogens has an impact on the SP-A"/>
 <result pre="2.1. Cell Culture For the single cell-culture, we use alveolar" exact="epithelial" post="cells. The human adenocarcinoma cell line NCI-H441 (ATCC, Manassas,"/>
 <result pre="the single cell-culture, we use alveolar epithelial cells. The human" exact="adenocarcinoma" post="cell line NCI-H441 (ATCC, Manassas, VA, USA) was cultivated"/>
 <result pre="cultivated in RPMI-medium (Roswell Park Memorial Institute medium, Gibco, Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) and supplemented with 10% inactivated"/>
 <result pre="being sub-cultured and used until the 18th passage. Besides this," exact="primary" post="monocytes were isolated from whole peripheral blood of healthy"/>
 <result pre="18th passage. Besides this, primary monocytes were isolated from whole" exact="peripheral" post="blood of healthy donors. The blood was diluted in"/>
 <result pre="(including afferent and efferent channels), and the volume of the" exact="epithelial" post="chamber is 120 µL (also including the channels). Peristaltic"/>
 <result pre="The random-wise analysis of the macrophage density observed a typical" exact="monocyte" post="differentiation rate of 90% without donor-specific variations. These data"/>
 <result pre="kidney (MDCK) cells. MDCKs were cultured in EMEM (Eagle’s Minimum" exact="Essential" post="Medium, ATCC, Wesel, Germany), supplemented with 10% fetal calve"/>
 <result pre="variant HA-D222-mpJena/5258, expressing an aspartate in position 222 of the" exact="viral" post="hemagglutinin, was passaged on MDCK. HA-D222-mpJena/5258 was obtained after"/>
 <result pre="virus isolate A/Jena/5258/09 (kindly provided by Andi Krumbholz [28]. The" exact="bacterial infection" post="was performed with a methicillin-resistant S. aureus/USA300/wild type (WT),"/>
 <result pre="isolate A/Jena/5258/09 (kindly provided by Andi Krumbholz [28]. The bacterial" exact="infection" post="was performed with a methicillin-resistant S. aureus/USA300/wild type (WT),"/>
 <result pre="aureus/USA300/wild type (WT), kindly provided by Lorena Tuchscherr [29]. The" exact="bacterial" post="strain S. aureus USA300 was grown overnight in brain"/>
 <result pre="bacterial strain S. aureus USA300 was grown overnight in brain" exact="heart" post="infusion (BHI)-medium at 37 °C with shaking. All bacteria"/>
 <result pre="S. aureus were determined weekly to calculate the number of" exact="infectious" post="particles in the cryopreserved bacterial working solution and to"/>
 <result pre="to calculate the number of infectious particles in the cryopreserved" exact="bacterial" post="working solution and to exclude changes in the number"/>
 <result pre="freezing. The determination of the S. aureus load after the" exact="infection" post="was performed by using the supernatants. For this, the"/>
 <result pre="counted to detect the number of bacteria. 2.4. In Vitro" exact="Infection" post="For the viral infection of the NCI-H441 mono-cell culture"/>
 <result pre="the number of bacteria. 2.4. In Vitro Infection For the" exact="viral infection" post="of the NCI-H441 mono-cell culture as well as the"/>
 <result pre="number of bacteria. 2.4. In Vitro Infection For the viral" exact="infection" post="of the NCI-H441 mono-cell culture as well as the"/>
 <result pre="infection of the NCI-H441 mono-cell culture as well as the" exact="infection" post="on the human alveolus-on-a-chip model, cells were washed with"/>
 <result pre="of the pathogen concentration, we have used the multiplicity of" exact="infection" post="(MOI). This information describes the ratio of pathogens to"/>
 <result pre="describes the ratio of pathogens to infected cells. For the" exact="viral infection" post="of the NCI-H441 cells we use MOI 1. The"/>
 <result pre="the ratio of pathogens to infected cells. For the viral" exact="infection" post="of the NCI-H441 cells we use MOI 1. The"/>
 <result pre="infection of the NCI-H441 cells we use MOI 1. The" exact="bacterial infection" post="on NCI-H441 cells was performed with RPMI (Roswell Park"/>
 <result pre="of the NCI-H441 cells we use MOI 1. The bacterial" exact="infection" post="on NCI-H441 cells was performed with RPMI (Roswell Park"/>
 <result pre="performed with RPMI (Roswell Park Memorial Institute 1640, Gibco, Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) with 1% human serum albumin"/>
 <result pre="human serum albumin (HSA) and 1mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The" exact="epithelial" post="side of the human alveolus-on-a-chip model was infected with"/>
 <result pre="HEPES, 10 ng/mL GM-CSF) with bacteria (MOI 5). After the" exact="bacterial infection" post="was performed, cells were incubated with bacteria for 90"/>
 <result pre="10 ng/mL GM-CSF) with bacteria (MOI 5). After the bacterial" exact="infection" post="was performed, cells were incubated with bacteria for 90"/>
 <result pre="pathogens were added to the cells. For this, first, the" exact="infection" post="with IV strain A/Puerto Rico/8 (MOI 1) was performed,"/>
 <result pre="strain A/Puerto Rico/8 (MOI 1) was performed, followed by the" exact="bacterial infection" post="with S. aureus/USA300/WT (MOI 5). For the infection of"/>
 <result pre="A/Puerto Rico/8 (MOI 1) was performed, followed by the bacterial" exact="infection" post="with S. aureus/USA300/WT (MOI 5). For the infection of"/>
 <result pre="the bacterial infection with S. aureus/USA300/WT (MOI 5). For the" exact="infection" post="of the single cell-culture of hMdM, cells were isolated"/>
 <result pre="without centrifugation until the indicated time points. For the single" exact="bacterial infection" post="as well as the co-infection, we use S. aureus/USA300/WT"/>
 <result pre="centrifugation until the indicated time points. For the single bacterial" exact="infection" post="as well as the co-infection, we use S. aureus/USA300/WT"/>
 <result pre="always contained a cell control (designated as mock), a single" exact="infection" post="with the virus, a single infection with bacteria, and"/>
 <result pre="as mock), a single infection with the virus, a single" exact="infection" post="with bacteria, and a co-infection. All cells were treated"/>
 <result pre="the mock-treated cells of the cell control. 2.5. In Vivo" exact="Infection" post="For the murine pneumonia model the mice were purchased"/>
 <result pre="the cell control. 2.5. In Vivo Infection For the murine" exact="pneumonia" post="model the mice were purchased from Janvier Labs (Le"/>
 <result pre="are housed in separate units, which are monitored frequently. Eight-week-old" exact="female" post="C57bl/6 mice were infected with the IV strain HA-D222-mpJena/5258,"/>
 <result pre="NaCl (mock-treated). The same method was used for S. aureus" exact="infection" post="(1 × 107 CFUs) two days later. During the"/>
 <result pre="infection (1 × 107 CFUs) two days later. During the" exact="infection" post="period, the state of the animal health was monitored"/>
 <result pre="of blood and lung were subjected to further analysis. The" exact="viral" post="titer and the bacterial counts of infected mice were"/>
 <result pre="were subjected to further analysis. The viral titer and the" exact="bacterial" post="counts of infected mice were determined in the right"/>
 <result pre="ERc5S). 2.6. Quantitative Real-Time PCR For quantitative real-time PCR, cell" exact="infection" post="was conducted as described above. Isolation of total RNA"/>
 <result pre="PCR, cell infection was conducted as described above. Isolation of" exact="total" post="RNA from macrophages, NCI-H441 and homogenized lungs was done"/>
 <result pre="model were first homogenized using the QIAshredder homogenizers (Qiagen) and" exact="total" post="RNA was isolated with RNeasy Micro Kit (Qiagen) following"/>
 <result pre="expression of SP-A, we have compared the data from the" exact="infection" post="with the pathogens and the data of the stimulation"/>
 <result pre="For this, we used 10 nM of TNF-α (Gibco, Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) added to RPMI. After 30"/>
 <result pre="Afterward, the mRNA expression was performed as described above. 2.7." exact="Protein" post="Analysis For the detection of extracellular TNF-α we performed"/>
 <result pre="Analysis For the detection of extracellular TNF-α we performed the" exact="infection" post="of the cells with virus, bacteria and both pathogens"/>
 <result pre="96-well plate in duplicates (Human TNF-α ELISA Kit, Invitrogen, Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) and subsequently analyzed according to"/>
 <result pre="the identification of SP-A, we used NCI-H441-cells and performed the" exact="infection" post="as previously described [25]. Next, 4 h and 18"/>
 <result pre="transferred in duplicates to a coated 96-well plate (Human SFTPA1/Surfactant" exact="Protein" post="A ELISA Kit, Sandwich ELISA, LifeSpan BioSciences, Inc., Seattle,"/>
 <result pre="Inflammation Panel (13-plex) (BioLegend, San Diego, CA, USA) was used." exact="Alveolar" post="biochips were infected as previously described and 4 h"/>
 <result pre="antibodies (Santa Cruz Biotechnologies, Dallas, TX, USA). Thereafter, fluorescent labeled" exact="secondary" post="antibodies (donkey-anti-goat- AlexaFlour647, life technologies, Carlsbad, CA, USA) were"/>
 <result pre="images were segmented in Imaris 9.2.1 (Bitplane, Zürich, Switzerland). The" exact="complete" post="process was published before [25]. 2.11. Statistical Analysis All"/>
 <result pre="the SP-A production we used single cell cultures of alveolar" exact="epithelial" post="cells type II (NCI-H441 cells). To verify an efficient"/>
 <result pre="production we used single cell cultures of alveolar epithelial cells" exact="type II" post="(NCI-H441 cells). To verify an efficient infection, viral titers"/>
 <result pre="cells type II (NCI-H441 cells). To verify an efficient infection," exact="viral" post="titers (Figure 1A), as well as viable bacteria, were"/>
 <result pre="1C). Next, we evaluated the protein levels of SP-A in" exact="epithelial" post="supernatants. Here we were able to show that SP-A"/>
 <result pre="show that SP-A is significantly decreased after 18 h of" exact="bacterial" post="mono- or co-infection (Figure 1D). This finding can be"/>
 <result pre="SP-A. We have verified the presence of ssPA in the" exact="bacterial" post="strain S. aureus USA300 by using the PanStaph Alere"/>
 <result pre="cells and induce strong proinflammatory and cytotoxic effects [31]. During" exact="viral" post="and/or bacterial infection, the cytokine profile, including the expression"/>
 <result pre="induce strong proinflammatory and cytotoxic effects [31]. During viral and/or" exact="bacterial infection," post="the cytokine profile, including the expression of TNF-α, of"/>
 <result pre="the host cell type and on the pathogens. In an" exact="epithelial" post="mono-cell culture (NCI-H441 cells) bacterial infection caused a much"/>
 <result pre="on the pathogens. In an epithelial mono-cell culture (NCI-H441 cells)" exact="bacterial infection" post="caused a much lower increase in TNF-α mRNA-expression compared"/>
 <result pre="the pathogens. In an epithelial mono-cell culture (NCI-H441 cells) bacterial" exact="infection" post="caused a much lower increase in TNF-α mRNA-expression compared"/>
 <result pre="epithelial mono-cell culture (NCI-H441 cells) bacterial infection caused a much" exact="lower" post="increase in TNF-α mRNA-expression compared to the infection of"/>
 <result pre="a much lower increase in TNF-α mRNA-expression compared to the" exact="infection" post="of immune cells (hMdM) (Figure 3). Here, we measured"/>
 <result pre="up to a 6-log increase of the TNF-α mRNA-expression after" exact="bacterial infections." post="Macrophage differentiation from monocytes was proven by performing single-cell"/>
 <result pre="summary, our results show that TNF-α expression after S. aureus" exact="infection" post="was much higher in macrophages than in epithelial cells,"/>
 <result pre="S. aureus infection was much higher in macrophages than in" exact="epithelial" post="cells, whereas IAV-infection did not significantly increase the TNF-α"/>
 <result pre="Downregulation Mainly Triggered by Bacteria Within the human alveolus-on-a-chip model," exact="epithelial" post="cells (NCI-H441), endothelial cells (HUVECs) and macrophages (hMdM) were"/>
 <result pre="under perfusion of the endothelial side and infected via the" exact="epithelial" post="side with the pathogens as indicated. The successful viral"/>
 <result pre="the epithelial side with the pathogens as indicated. The successful" exact="viral infection" post="was proven by the budding process of IAV, as"/>
 <result pre="epithelial side with the pathogens as indicated. The successful viral" exact="infection" post="was proven by the budding process of IAV, as"/>
 <result pre="we could visualize the adherence of S. aureus on the" exact="epithelial" post="surface within the alveolus-on-a-chip model (Figure 4A). In this"/>
 <result pre="TNF-α release (Figure 4B). To evaluate the impact of the" exact="infection" post="and subsequent TNF-α expression on the production of SP-A,"/>
 <result pre="content by immunofluorescence staining in the human alveolus-on-a-chip model following" exact="infection" post="with IAV, S. aureus or co-infection (Figure 4C). By"/>
 <result pre="fluorescence intensity (MFI) we detected decreased levels of SP-A following" exact="infection" post="by S. aureus and in the co-infection scenario (Figure"/>
 <result pre="S. aureus Downregulates SP-A Expression in a Murine Model of" exact="Pneumonia" post="Finally, to reproduce the results obtained in the cell-culture"/>
 <result pre="in the cell-culture systems in an in vivo murine lung" exact="infection" post="model, we established a pneumonia model and infected the"/>
 <result pre="an in vivo murine lung infection model, we established a" exact="pneumonia" post="model and infected the mice with IAV, S. aureus"/>
 <result pre="both pathogens. After day 4 mice were sacrificed and the" exact="bacterial" post="counts in the lung tissue were determined. Furthermore, the"/>
 <result pre="mRNA-expression of SP-A was quantified. Our results show a high" exact="viral" post="load (PFU/mL) 4 days p.i. (Figure 5A). Similarly, bacterial"/>
 <result pre="high viral load (PFU/mL) 4 days p.i. (Figure 5A). Similarly," exact="bacterial infection" post="resulted in detectable CFUs within the lung tissue of"/>
 <result pre="viral load (PFU/mL) 4 days p.i. (Figure 5A). Similarly, bacterial" exact="infection" post="resulted in detectable CFUs within the lung tissue of"/>
 <result pre="we could clearly show that the SP-A expression within the" exact="bacterial" post="mono- and co-infection was down-regulated four days after infection,"/>
 <result pre="SP-A expression (Figure 5C). To further analyze the effect of" exact="viral" post="and/or bacterial infection in the murine model system, we"/>
 <result pre="(Figure 5C). To further analyze the effect of viral and/or" exact="bacterial infection" post="in the murine model system, we performed histopathological staining"/>
 <result pre="5C). To further analyze the effect of viral and/or bacterial" exact="infection" post="in the murine model system, we performed histopathological staining"/>
 <result pre="of the alveolar structures that was caused by a bacterial," exact="viral" post="or co-infection (Figure 5D). These results indicate that infections"/>
 <result pre="bacterial, viral or co-infection (Figure 5D). These results indicate that" exact="infections" post="can trigger lung inflammation by different mechanisms that can"/>
 <result pre="co-infection (Figure 5D). These results indicate that infections can trigger" exact="lung inflammation" post="by different mechanisms that can be dependent (S. aureus"/>
 <result pre="infection) or independent (IAV infection) on SP-A expression. 4. Discussion" exact="Secondary" post="bacterial pneumonia is one of the main reasons for"/>
 <result pre="or independent (IAV infection) on SP-A expression. 4. Discussion Secondary" exact="bacterial" post="pneumonia is one of the main reasons for increased"/>
 <result pre="independent (IAV infection) on SP-A expression. 4. Discussion Secondary bacterial" exact="pneumonia" post="is one of the main reasons for increased morbidity"/>
 <result pre="response is also involved in the severe outcome of concomitant" exact="bacterial" post="and viral infections. The pulmonary surfactant plays an important"/>
 <result pre="also involved in the severe outcome of concomitant bacterial and" exact="viral" post="infections. The pulmonary surfactant plays an important role as"/>
 <result pre="the severe outcome of concomitant bacterial and viral infections. The" exact="pulmonary" post="surfactant plays an important role as the first line"/>
 <result pre="and neutrophils via agglutination and opsonization of pathogens [14]. The" exact="deficiency" post="of surfactant proteins can lead to various diseases. First"/>
 <result pre="of all, in premature infants, the insufficient surfactant production causes" exact="neonatal respiratory distress syndrome" post="(RDS) [32]. A decreased SP-A level in amniotic fluid"/>
 <result pre="all, in premature infants, the insufficient surfactant production causes neonatal" exact="respiratory" post="distress syndrome (RDS) [32]. A decreased SP-A level in"/>
 <result pre="premature infants, the insufficient surfactant production causes neonatal respiratory distress" exact="syndrome" post="(RDS) [32]. A decreased SP-A level in amniotic fluid"/>
 <result pre="tracheal aspirates [34]. There are two therapeutic approaches in imminent" exact="premature birth." post="The prenatal administration of corticosteroids, particularly Betamethasone, accelerates lung"/>
 <result pre="surfactant [39]. Early administration of surfactant reduces the risk of" exact="pneumothorax" post="and decreases mortality rates in preterm children [40]. Particularly"/>
 <result pre="improves the outcome of infants with RDS [41]. Furthermore, the" exact="adult" post="acute respiratory distress syndrome (ARDS) is also associated with"/>
 <result pre="the outcome of infants with RDS [41]. Furthermore, the adult" exact="acute respiratory distress syndrome" post="(ARDS) is also associated with a decreased amount of"/>
 <result pre="outcome of infants with RDS [41]. Furthermore, the adult acute" exact="respiratory" post="distress syndrome (ARDS) is also associated with a decreased"/>
 <result pre="infants with RDS [41]. Furthermore, the adult acute respiratory distress" exact="syndrome" post="(ARDS) is also associated with a decreased amount of"/>
 <result pre="surfactant phospholipids [42]. In agreement with this result patients with" exact="respiratory" post="failure aggravated by sepsis also had a decreased surfactant"/>
 <result pre="sepsis also had a decreased surfactant level [43] indicating that" exact="infections" post="can worsen the already low surfactant amount in patients"/>
 <result pre="were found in the bronchoalveolar lavage (BAL) of patients with" exact="pneumonia" post="and without ARDS [44,45]. These examples demonstrate the great"/>
 <result pre="and also the possibility to improve the lung function by" exact="external" post="surfactant administration during a state of deficiency. S. aureus"/>
 <result pre="The direct effect of extracellular S. aureus proteases impairs the" exact="bacterial" post="clearance and results in enhanced adherence and invasion of"/>
 <result pre="results in enhanced adherence and invasion of S. aureus to" exact="epithelial" post="cells [21]. Additionally, surfactant proteins affect IAV infection [12]."/>
 <result pre="aureus to epithelial cells [21]. Additionally, surfactant proteins affect IAV" exact="infection" post="[12]. However, an interfering effect of IAV infection on"/>
 <result pre="affect IAV infection [12]. However, an interfering effect of IAV" exact="infection" post="on SP-A has not been described. The regulation of"/>
 <result pre="a consequence, an increased TNF-α level during an S. aureus" exact="infection" post="hampers the function of SP-A. It is well known"/>
 <result pre="function of SP-A. It is well known that S. aureus" exact="infections" post="lead to a high release of TNF-α, in particular"/>
 <result pre="as macrophages. Yet, TNF-α expression was not increased upon IAV" exact="infection" post="in immune cells within the present experimental setting. Although"/>
 <result pre="present experimental setting. Although SP-A is mainly produced by alveolar-epithelial" exact="type II" post="cells, other cell types, such as endothelial and immune"/>
 <result pre="vitro in a mono-cell culture system. Consequently, the response to" exact="infection" post="in the lung is highly complex and requires appropriate"/>
 <result pre="types interact with each other. Frequently used models to study" exact="infections" post="are mice. Here, the infection can be analyzed in"/>
 <result pre="Frequently used models to study infections are mice. Here, the" exact="infection" post="can be analyzed in the complete organ, including damages"/>
 <result pre="are mice. Here, the infection can be analyzed in the" exact="complete" post="organ, including damages in the alveolar structures. Yet, the"/>
 <result pre="differ from human cells. For example, the action of defined" exact="bacterial" post="toxins (e.g., superantigens and leucocidins) can be very species-specific"/>
 <result pre="mRNA expression of SP-A in NCI-H441 mono-cell culture, indicating that" exact="bacterial" post="and viral pathogens do not affect the SP-A expression"/>
 <result pre="of SP-A in NCI-H441 mono-cell culture, indicating that bacterial and" exact="viral" post="pathogens do not affect the SP-A expression within the"/>
 <result pre="viral pathogens do not affect the SP-A expression within the" exact="epithelial" post="cells. Furthermore, our results demonstrate that TNF-α is a"/>
 <result pre="of TNF-α, in particular in hMdM cells. By contrast, IAV" exact="infection" post="has only a minor effect on TNF-α synthesis, which"/>
 <result pre="alveolus-on-a-chip model demonstrates high amounts of TNF-α in response to" exact="bacterial infection." post="Finally, through MFI quantification we could demonstrate that bacterial"/>
 <result pre="bacterial infection. Finally, through MFI quantification we could demonstrate that" exact="bacterial infection" post="significantly decreased intracellular SP-A protein levels. Additionally, we have"/>
 <result pre="infection. Finally, through MFI quantification we could demonstrate that bacterial" exact="infection" post="significantly decreased intracellular SP-A protein levels. Additionally, we have"/>
 <result pre="of extracellular SP-A, there is an indirect effect based on" exact="infection" post="via the cytokine production, notably by TNF-α. During infection,"/>
 <result pre="for elevated TNF-α levels that have already been described to" exact="lower" post="mRNA levels of SP-A. Therefore, we concluded that an"/>
 <result pre="Therefore, we concluded that an interaction of macrophages and alveolar" exact="epithelial" post="cells decrease SP-A mRNA levels. These data demonstrate that"/>
 <result pre="SP-A mRNA levels. These data demonstrate that the analysis of" exact="infection" post="processes requires the use of sophisticated model systems that"/>
 <result pre="various human cells and mimic the organ system. 5. Conclusions" exact="Pneumonia" post="is the leading cause of morbidity and mortality worldwide"/>
 <result pre="Our study investigated the impact of IV and/or S. aureus" exact="infection" post="on the SP-A expression in vitro and in vivo."/>
 <result pre="and in vivo. We can show that complex interactions of" exact="epithelial" post="cells and immune cells result in the down-regulation of"/>
 <result pre="cells result in the down-regulation of SP-A mRNA expression. Furthermore," exact="bacterial" post="mono- and super-infections reduce the SP-A expression in a"/>
 <result pre="murine model which might contribute to the severe outcome of" exact="bacterial" post="pneumonia. Acknowledgments We thank Elke Teuscher for supplying umbilical"/>
 <result pre="remaining authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships considered as a potential"/>
 <result pre="Structure, function and receptorsMol. Immunol.2006431293131510.1016/j.molimm.2005.08.00416213021 8.HanS.MallampalliR.K.The role of surfactant in" exact="lung disease" post="and host defense against pulmonary infectionsAnn. Am. Thorac. Soc.20151276577410.1513/AnnalsATS.201411-507FR25742123"/>
 <result pre="function and receptorsMol. Immunol.2006431293131510.1016/j.molimm.2005.08.00416213021 8.HanS.MallampalliR.K.The role of surfactant in lung" exact="disease" post="and host defense against pulmonary infectionsAnn. Am. Thorac. Soc.20151276577410.1513/AnnalsATS.201411-507FR25742123"/>
 <result pre="role of surfactant in lung disease and host defense against" exact="pulmonary" post="infectionsAnn. Am. Thorac. Soc.20151276577410.1513/AnnalsATS.201411-507FR25742123 9.BenneC.A.KraaijeveldC.A.van StrijpJ.A.BrouwerE.HarmsenM.VerhoefJ.van GoldeL.M.van IwaardenJ.F.Interactions of"/>
 <result pre="class AJ. Biol. Chem.20112864854487010.1074/jbc.M110.12556721123169 14.WispeJ.R.ClarkJ.C.WarnerB.B.FajardoD.HullW.E.HoltzmanR.B.WhitsettJ.A.Tumor necrosis factor-alpha inhibits expression of" exact="pulmonary" post="surfactant proteinJ. Clin. Investig.1990861954196010.1172/JCI1149292123888 15.IslamK.N.MendelsonC.R.Potential role of nuclear factor"/>
 <result pre="and cytokine regulation of surfactant protein-a gene expression in lung" exact="type II" post="cellsMol. Endocrinol.2002161428144012040027 16.ItoY.MasonR.J.The effect of interleukin-13 (IL-13) and interferon-γ"/>
 <result pre="(IL-13) and interferon-γ (IFN-γ) on expression of surfactant proteins in" exact="adult" post="human alveolar type II cells in vitroRespir. Res.20101115710.1186/1465-9921-11-15721067601 17.VäyrynenO.GlumoffV.HallmanM.Regulation"/>
 <result pre="(IFN-γ) on expression of surfactant proteins in adult human alveolar" exact="type II" post="cells in vitroRespir. Res.20101115710.1186/1465-9921-11-15721067601 17.VäyrynenO.GlumoffV.HallmanM.Regulation of surfactant proteins by"/>
 <result pre="diverse forms of macrophage activation and polarizationTrends Immunol.20042567768610.1016/j.it.2004.09.01515530839 20.GongJ.H.SprengerH.HinderF.BenderA.SchmidtA.HorchS.NainM.GemsaD.Influenza A" exact="virus infection" post="of macrophages. Enhanced tumor necrosis factor-alpha (TNF-alpha) gene expression"/>
 <result pre="forms of macrophage activation and polarizationTrends Immunol.20042567768610.1016/j.it.2004.09.01515530839 20.GongJ.H.SprengerH.HinderF.BenderA.SchmidtA.HorchS.NainM.GemsaD.Influenza A virus" exact="infection" post="of macrophages. Enhanced tumor necrosis factor-alpha (TNF-alpha) gene expression"/>
 <result pre="and polarizationTrends Immunol.20042567768610.1016/j.it.2004.09.01515530839 20.GongJ.H.SprengerH.HinderF.BenderA.SchmidtA.HorchS.NainM.GemsaD.Influenza A virus infection of macrophages. Enhanced" exact="tumor" post="necrosis factor-alpha (TNF-alpha) gene expression and lipopolysaccharide-triggered TNF-alpha releaseJ."/>
 <result pre="factor-alpha (TNF-alpha) gene expression and lipopolysaccharide-triggered TNF-alpha releaseJ. Immunol.199114735071940351 21.CuiW.MorrisonD.C.SilversteinR.Differential" exact="tumor" post="necrosis factor alpha expression and release from peritoneal mouse"/>
 <result pre="bacteriaInfect. Immun.2000684422442910.1128/IAI.68.8.4422-4429.200010899839 22.OliveiraD.BorgesA.SimõesM.Staphylococcus aureus toxins and their molecular activity in" exact="infectious" post="diseasesToxins20181025225210.3390/toxins1006025229921792 23.KantykaT.PyrcK.GrucaM.SmagurJ.PlazaK.GuzikK.ZeglenS.OchmanM.PotempaJ.Staphylococcus aureus proteases degrade lung surfactant protein A"/>
 <result pre="cell layers with improved perfusion conditionsBiofabrication2015701501310.1088/1758-5090/7/1/01501325727374 25.Deinhardt-EmmerS.RennertK.SchickeE.CseresnyesZ.WindolphM.NietzscheS.HellerR.SiwczakF.HauptK.F.CarlstedtS.et al.Co-infection withStaphylococcus aureusafter" exact="primary" post="influenza virus infection leads to damage of the endothelium"/>
 <result pre="with improved perfusion conditionsBiofabrication2015701501310.1088/1758-5090/7/1/01501325727374 25.Deinhardt-EmmerS.RennertK.SchickeE.CseresnyesZ.WindolphM.NietzscheS.HellerR.SiwczakF.HauptK.F.CarlstedtS.et al.Co-infection withStaphylococcus aureusafter primary influenza" exact="virus infection" post="leads to damage of the endothelium in a human"/>
 <result pre="improved perfusion conditionsBiofabrication2015701501310.1088/1758-5090/7/1/01501325727374 25.Deinhardt-EmmerS.RennertK.SchickeE.CseresnyesZ.WindolphM.NietzscheS.HellerR.SiwczakF.HauptK.F.CarlstedtS.et al.Co-infection withStaphylococcus aureusafter primary influenza virus" exact="infection" post="leads to damage of the endothelium in a human"/>
 <result pre="modeling approachBio Syst.2014118515910.1016/j.biosystems.2014.02.004 29.TuchscherrL.MedinaE.HussainM.VolkerW.HeitmannV.NiemannS.HolzingerD.RothJ.ProctorR.A.BeckerK.et al.Staphylococcus aureus phenotype switching: An effective" exact="bacterial" post="strategy to escape host immune response and establish a"/>
 <result pre="bacterial strategy to escape host immune response and establish a" exact="chronic" post="infectionEMBO Mol. Med.2011312914110.1002/emmm.20100011521268281 30.PfafflM.W.A new mathematical model for relative"/>
 <result pre="Obstet. Gynecol.1984148485310.1016/S0002-9378(84)80031-96546325 34.ChidaS.PhelpsD.S.CordleC.SollR.FlorosJ.TaeuschH.W.Surfactant-associated proteins in tracheal aspirates of infants with" exact="respiratory" post="distress syndrome after surfactant therapyAm. Rev. Respir. Dis.198813794394710.1164/ajrccm/137.4.9433355003 35.LigginsG.C.HowieR.N.A"/>
 <result pre="34.ChidaS.PhelpsD.S.CordleC.SollR.FlorosJ.TaeuschH.W.Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress" exact="syndrome" post="after surfactant therapyAm. Rev. Respir. Dis.198813794394710.1164/ajrccm/137.4.9433355003 35.LigginsG.C.HowieR.N.A controlled trial"/>
 <result pre="controlled trial of antepartum glucocorticoid treatment for prevention of the" exact="respiratory" post="distress syndrome in premature infantsPediatrics1972505155254561295 36.deLemosR.A.ShermetaD.W.KnelsonJ.H.KotasR.AveryM.E.Acceleration of appearance of"/>
 <result pre="of antepartum glucocorticoid treatment for prevention of the respiratory distress" exact="syndrome" post="in premature infantsPediatrics1972505155254561295 36.deLemosR.A.ShermetaD.W.KnelsonJ.H.KotasR.AveryM.E.Acceleration of appearance of pulmonary surfactant"/>
 <result pre="respiratory distress syndrome in premature infantsPediatrics1972505155254561295 36.deLemosR.A.ShermetaD.W.KnelsonJ.H.KotasR.AveryM.E.Acceleration of appearance of" exact="pulmonary" post="surfactant in the fetal lamb by administration of corticosteroidsAm."/>
 <result pre="by administration of corticosteroidsAm. Rev. Respir. Dis.19701024594615450911 37.KotasR.V.AveryM.E.Accelerated appearance of" exact="pulmonary" post="surfactant in the fetal rabbitJ. Appl. Physiol.19713035836110.1152/jappl.1971.30.3.3585544115 38.GuarinoN.OueT.ShimaH.PuriP.Antenatal dexamethasone"/>
 <result pre="enhances surfactant protein synthesis in the hypoplastic lung of nitrofen-induced" exact="diaphragmatic hernia" post="in ratsJ. Pediatr. Surg.2000351468147310.1053/jpsu.2000.1641611051153 39.KonishiM.FujiwaraT.NaitoT.TakeuchiY.OgawaY.InukaiK.FujimuraM.NakamuraH.HashimotoT.Surfactant replacement therapy in neonatal"/>
 <result pre="diaphragmatic hernia in ratsJ. Pediatr. Surg.2000351468147310.1053/jpsu.2000.1641611051153 39.KonishiM.FujiwaraT.NaitoT.TakeuchiY.OgawaY.InukaiK.FujimuraM.NakamuraH.HashimotoT.Surfactant replacement therapy in" exact="neonatal respiratory distress syndrome." post="A multi-centre, randomized clinical trial: Comparison of high- versus"/>
 <result pre="hernia in ratsJ. Pediatr. Surg.2000351468147310.1053/jpsu.2000.1641611051153 39.KonishiM.FujiwaraT.NaitoT.TakeuchiY.OgawaY.InukaiK.FujimuraM.NakamuraH.HashimotoT.Surfactant replacement therapy in neonatal" exact="respiratory" post="distress syndrome. A multi-centre, randomized clinical trial: Comparison of"/>
 <result pre="J. Obstet. Gynecol.199316850851310.1016/0002-9378(93)90483-Y8438919 42.GregoryT.LongmoreW.MoxleyM.WhitsettJ.ReedC.FowlerA.R.HudsonL.MaunderR.CrimC.HyersT.Surfactant chemical composition and biophysical activity in" exact="acute" post="respiratory distress syndromeJ. Clin. Investig.1991881976198110.1172/JCI1155231752956 43.PisonU.ObertackeU.BrandM.SeegerW.JokaT.BruchJ.Schmit-NeuerburgK.Altered pulmonary surfactant in"/>
 <result pre="Obstet. Gynecol.199316850851310.1016/0002-9378(93)90483-Y8438919 42.GregoryT.LongmoreW.MoxleyM.WhitsettJ.ReedC.FowlerA.R.HudsonL.MaunderR.CrimC.HyersT.Surfactant chemical composition and biophysical activity in acute" exact="respiratory" post="distress syndromeJ. Clin. Investig.1991881976198110.1172/JCI1155231752956 43.PisonU.ObertackeU.BrandM.SeegerW.JokaT.BruchJ.Schmit-NeuerburgK.Altered pulmonary surfactant in uncomplicated"/>
 <result pre="biophysical activity in acute respiratory distress syndromeJ. Clin. Investig.1991881976198110.1172/JCI1155231752956 43.PisonU.ObertackeU.BrandM.SeegerW.JokaT.BruchJ.Schmit-NeuerburgK.Altered" exact="pulmonary" post="surfactant in uncomplicated and septicemia-complicated courses of acute respiratory"/>
 <result pre="Investig.1991881976198110.1172/JCI1155231752956 43.PisonU.ObertackeU.BrandM.SeegerW.JokaT.BruchJ.Schmit-NeuerburgK.Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of" exact="acute" post="respiratory failureJ. Trauma199030192610.1097/00005373-199001000-000032296063 44.BaughmanR.P.SternbergR.I.HullW.BuchsbaumJ.A.WhitsettJ.Decreased surfactant protein A in patients"/>
 <result pre="43.PisonU.ObertackeU.BrandM.SeegerW.JokaT.BruchJ.Schmit-NeuerburgK.Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute" exact="respiratory" post="failureJ. Trauma199030192610.1097/00005373-199001000-000032296063 44.BaughmanR.P.SternbergR.I.HullW.BuchsbaumJ.A.WhitsettJ.Decreased surfactant protein A in patients with"/>
 <result pre="respiratory failureJ. Trauma199030192610.1097/00005373-199001000-000032296063 44.BaughmanR.P.SternbergR.I.HullW.BuchsbaumJ.A.WhitsettJ.Decreased surfactant protein A in patients with" exact="bacterial" post="pneumoniaAm. Rev. Respir. Dis.199314765365710.1164/ajrccm/147.3.6538442601 45.LeVineA.M.LotzeA.StanleyS.StroudC.O’DonnellR.WhitsettJ.PollackM.M.Surfactant content in children with"/>
 <result pre="diseaseCrit. Care Med.1996241062106710.1097/00003246-199606000-000298681574 46.MiakotinaO.L.SnyderJ.M.TNF-α inhibits SP-A gene expression in lung" exact="epithelial" post="cells via p38 MAPKAm. J. Physiol. Lung Cell. Mol."/>
 <result pre="necrosis factor alpha exerts powerful anti-influenza virus effects in lung" exact="epithelial" post="cellsJ. Virol.2002761071107610.1128/JVI.76.3.1071-1076.200211773383 Figure 1 NCI-H441 cells were productively infected"/>
 <result pre="upon mono- and co-infection with S. aureus USA300 (A). The" exact="bacterial" post="load increases over time upon mono- and viral co-infection"/>
 <result pre="(A). The bacterial load increases over time upon mono- and" exact="viral" post="co-infection (B). The infection of epithelial cells does not"/>
 <result pre="increases over time upon mono- and viral co-infection (B). The" exact="infection" post="of epithelial cells does not affect the mRNA expression"/>
 <result pre="time upon mono- and viral co-infection (B). The infection of" exact="epithelial" post="cells does not affect the mRNA expression of SP-A,"/>
 <result pre="Extracellular SP-A levels are decreased in the supernatants of the" exact="epithelial" post="cell culture system after S. aureus infection, as well"/>
 <result pre="expression is significantly higher in immune cells (hMdM) than in" exact="epithelial" post="cells (NCI-H441) after bacterial mono- or co-infection. Mock-treated cells"/>
 <result pre="in immune cells (hMdM) than in epithelial cells (NCI-H441) after" exact="bacterial" post="mono- or co-infection. Mock-treated cells obtained the same medium"/>
 <result pre="and co-infection measured in pg/mL. (C) Immunofluorescence staining of the" exact="epithelial" post="cell side of the human alveolus-on-a-chip model shows SP-A"/>
 <result pre="p &amp;lt; 0.01. Figure 5 Murine model of S. aureus" exact="pneumonia" post="showing viral titers (A) as well as S. aureus"/>
 <result pre="0.01. Figure 5 Murine model of S. aureus pneumonia showing" exact="viral" post="titers (A) as well as S. aureus colony-forming units"/>
 <result pre="co-infection. Downregulation of SP-A mRNA expression is mainly caused by" exact="bacterial" post="mono- and co-infection (C). 100x magnification of the lung"/>
</results>
